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Abstract:  
 Human Cytomegalovirus (CMV) remains a major cause of morbidity and mortality after 
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Frequency of CMV infection and 
disease after allo-HSCT depend on several factors including virus-host interactions, recipient-donor 
CMV serology, donor type (HLA-identical vs. haplo-identical donors)and intensity of conditioning 
regimens. Moreover, monitoring strategies, cut-off values of viremia to guide prophylactic, pre-
emptive, and treatment interventions remain to be determined. Broader knowledge in CMV biology 
and its relationship with the host immune-system is greatly contributing to develop novel 
therapeutic approaches including the application of novel antiviral drugs, with improved toxicity 
profiles currently under investigation in randomized phase II and III trials, and cell therapy 
approaches. Significant evidence of the clinical efficacy of adoptive T-cell therapy (ATCT) from 
CMV-seropositive donors is also emerging. Alternative methods allow ATCT also in allo-HSCT 
recipients of seronegative donors and cord blood grafts. Vaccine-immunotherapy has the difficult 
task to reduce the incidence of CMV reactivation/infection in immunocompromised allo-HSCT 
patients and reach CMV immune control. In this manuscript, we update a previous review by also 
including recent developments in the virology lab and their possible association with treatment 
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 Despite remarkable improvements in diagnostic tests and treatments, management of CMV 
in HSCT recipients remains challenging. Standard treatment options for cytomegalovirus (CMV) 
reactivation/infection have for long been limited to a small number of effective drugs, most of them 
characterized by significant toxicities, high costs and the risk of promoting drug-resistant CMV 
strains. Ganciclovir (GCV) and its oral bio-available pro-drug valganciclovir remain the most 
widely used drugs in the setting of pre-emptive treatment. Although GCV lowered CMV 
reactivation in previous randomized controlled clinical trials, it failed to improve overall survival 
rates versus placebo in CMV prophylaxis among allogeneic hematopoietic stem cell transplant 
(allo-HCT) recipients primarily due to myelosuppressive effects resulting in clinically relevant 
multiple bacterial and fungalinfections
1–3
. Foscarnet, a virustatic DNA-polymerase inhibitor, 
represents an alternative to GCV due to the absence of myelotoxicity but its nephrotoxic effect 
coupled with marked serum electrolytes abnormalities, requires a very cautious approach, rendering 
its management potentially difficult 
4
. The emergence of drug-resistant CMV strains poses a 
continuous major threat to HSCT recipients, with relevant rates of morbidity, graft losses and, 
mortality. With the recent introduction of novel agents such letermovir, prevention of CMV 
infection in allo-HCT recipients may gradually change the clinical approach shifting the paradigm 
from preemptive strategies to effective prophylaxis. Moreover, the emerging role of cell-mediated 
immunologic monitoring and CMV specific viralogical testing may be of great help in clinical 
decision-making process. In this review, we also discuss the integration of novel antiviral therapies, 
including CMV specific T cell therapies, with standardized molecular tests that may lead to 
individualized prophylactic and therapeutical approaches. 
 
CMV infection and replication in human cells 
 CMV is a member of the family Herpesviridae, responsible for asymptomatic and generally 
benign self-limiting infections in immunocompetent subjects. CMV genome consists of 230 kbp 
linear double-stranded DNA encoding structural and functional proteins, for instance UL97 and 
UL54 that are extremely relevant in the context of anti-CMV agents. CMV is able to replicate in 
epithelial cells, fibroblasts and monocytes/macrophages. Once the CMV penetrate into the infected 
cell the viral DNA is transported into the nucleus for transcription. At this point, early genes initiate 
the replication of viral genome. CMV encodes for its own DNA polymerase and the result of CMV 
replication is a long DNA chain containing multiple repeated gene sequences known as 
concatemers. The production of infective virions requires the cleavage of the concatemeric DNA 
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into multiple monomers that will be eventually packaged into a viral capside prior to its release as 
an infective virion. These steps of maturation, packaging and termination are performed by a group 
of proteins defined as the “CMV terminase complex” including the pUL9 and pUL56 that interact 
synergistically. Once the terminase complex has cleaved the CMV concatemers, the CMV DNA is 
transported inside an empty viral procapsid by the interaction of the terminase complex and capsid 
proteins and finally the enveloped infectious particles are released. Of note, the structure of 
terminase complex is conserved across members of herperviridiae but it is not shared with human 
cells: accordingly, agents interacting with the terminase complex might be potentially virus-specific 
while preserving human cells. 
 
CMV infection and disease after allo-HSCT: the role of the virological evaluation  
 The frequency of CMV infection and disease after allo-HSCT relies on the interaction of 
several factors pertinent to the virus, the host, and the type of transplant.
6,7
Among virus-related 
factors, the development of CMV disease has directly been correlated with viral replication and 
related CMV DNAemia. Considering the antiviral strategies to prevent CMV disease, prophylaxis 
and pre-emptive therapy are commonly recognized as current standard approaches.
8–12
A recent 
systematic meta-analysis on the role of prophylaxis in HSCT and several controlled trials on the 
efficacy of different protocols for CMV prophylaxis have clearly showed the formidable role played 
by specific antiviral prophylaxis and pre-emptive therapies.
13
 In this setting, virological testing is 
pivotal. Close viral monitoring and initiation of antiviral treatment at a certain threshold of CMV 
DNAemia are crucial for effective pre-emptive strategies. In the past decades, an antigenemia assay, 
that allowed quantitative detection of CMV immediate early antigens pp65-UL83 in peripheral 
polymorphonuclear cells, played a key role in monitoring CMV reactivation and infections in both 
solid organ and allo-HSCT recipients and in guiding pre-emptive treatments. However, this assay 
has gradually become obsolete as it was labor- and time consuming, and highly operator-dependent. 
Presently, molecular methods such as commercial available, fully automated PCR assays represent 
the gold standard given their standardization. These technologies are completed by nucleic acid 
extraction platforms, implemented to extract and quantify CMV DNA from either plasma or whole 
blood specimens. Importantly, it is generally assumed that plasma CMV DNAemia is about 1-log10 
lower than whole blood DNAemia. Moreover, a recent Italian retrospective non-interventional 
multicenter cohort study described different kinetics of CMV DNA in blood and plasma with 
prolonged persistence of viral DNA in plasma rather than whole blood following ganciclovir 
treatment, despite adequate control of viral replication.
14
 These findings suggest that viral 
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monitoring on plasma samples may lead to an inappropriately prolonged antiviral treatment with 
inevitable increased risk of toxicity. Overall, whole blood DNAemia may therefore be preferred to 
guide pre-emptive treatment. It is at least strongly recommended to use the same biological fluid 




 Some issues that link virological testing with clinical approaches remain to be addressed. No 
definitive threshold of viral load for starting pre-emptive treatment has been determined. Some 
Authors have suggested that pre-emptive treatment should be started for levels of CMV-DNAemia> 
10,000 copies/mL in whole blood or >1000 copies/mL in plasma. A lower threshold could be 
considered in presence of high risk of viral disease (i.e. early infection within the first month post-
transplant, cord blood recipients, active anti-GVHD treatment after a transplant from haplo-
identical or mismatched unrelated donor, positive donor CMV serology and recipient negative, ex-
vivo or in-vivo T cell depletion). Considering viral kinetics, at least a threefold increase in viral load 
should be considered significant. When the cut-off threshold is reached, CMV DNAemia should be 
confirmed within a couple of days. Regardless of its duration, pre-emptive therapy should be 
discontinued in case of CMV-DNAemia clearance after two consecutive negative tests performed at 
least 3-4 days apart. This is particularly relevant to reduce the risk of selecting drug resistant strains. 
Another technical but relevant issue is the high variability of molecular assays for low CMV 
DNAemia loads (<1000 IU/mL). It may be reasonable to think that changes greater than threefold 
(0.5 log10 IU/mL) represent biologically important variations in viral replication with potential 
clinical impact.
16
Of note, when interpreting CMV DNAemia levels, close attention should be paid 
to the mechanism of action of the antiviral agent used for prophylaxis/pre-emptive therapy. In fact, 
while acyclovir, ganciclovir, valganciclovir and foscarnet inhibit viral replication by interfering 
with CMV DNA polymerase function, the more recently developed letermovir does not interfere 
with DNA synthesis but inhibits the terminase complex subunit pUL56 at a viral maturation and 
packaging stage of viral particles subsequent to viral DNA synthesis.
17,18
 Therefore, CMV 
DNAemia may remain longer detectable in patients receiving letermovir.
12
 Although this could be 
less relevant during prophylaxis, breakthrough CMV DNAemia in patients receiving prophylaxis 
with letermovir might be of difficult interpretation. Importantly, in 2010, the World Health 
Organization (WHO) International Reference Standard for CMV-DNA quantification was 
developed and approved. This allowed for the calibration of CMV-specific quantitative assays and 





 Among the host-related factors, pre-transplant CMV serostatus is considered the single most 
important predictor of CMV disease post-transplant with seronegative recipients from a seropositive 
donor (D+/R-) being at the highest risk; seropositive recipients (D+/R+; D-/R+) at intermediate risk, 
and D-/R- at the lowest risk
20–22
 According to a well-recognised clinical practice, pre-transplant 
serological evaluation for presence / absence of anti-CMV IgG must invariably be performed in 
both donor and recipient. Ifthe serological status is negative in donor and/or recipient, a re-
evaluation at the time of transplant should be recommended. If the recipient is seronegative, a 
seronegative donor should be selected when possible. Moreover, if CMV specific IgMs are 
detected, the viral load should be evaluated by molecular methods and, in the presence of CMV 
DNAemia, the candidate donor should temporarily be excluded from donation.  
CMV infection and CMV-specific T cell response  
 An important predictor of CMV infection/disease is represented by CMV-specific T cell 
response.
23,24
 Different methods to measure cellular immune response are available, including flow 
cytometry-based techniques and interferon gamma releasing assays (IGRAs). IGRAs have been 
developed to detect and quantify T-cell responses following antigen-specific stimulation and to give 
an indication of functional responsiveness.
25–30
 QuantiFERON-CMV is the only IGRA assay 
approved for CMV immune monitoring in the clinical setting. It consists in the quantification, by 
immuno-enzymatic technique, of the patient CMV-specific CD8+ Tcells following ex-vivo 
stimulation with CMV specific peptides and evaluation of IFN-γ release. QuantiFERON is simple 
and reproducible and has been validated in both SOT and allo-HSCT recipients. Another commonly 
employed IGRA is the CMV enzyme-linked immunospot (EliSPOT) assay for simultaneous 
detection and quantitation of both CD4+ and CD8+ T-cell responses. In the setting of allo-HSCT, 
evaluation of cellular immune response should be evaluated post-transplant when recipient 
lymphocytes against CMV have presumably been ablated and after engraftment when conditioning-
induced lymphopenia has been resolved. The threshold of CD3+ T cells number required for 
reliable testing has not yet been defined although some centers consider 100 T cells / ul as the 
minimum cut-off. In most studies on allo-HSCT patients, IGRAs were regularly performed (most 
commonly weekly or monthly) after engraftment for a variable period (during the first 100 days or 
the first 12 months post-transplant).
25–30
 In the presence of CMV-specific T-cell response in 
clinically stable recipients, no further evaluation is recommended. In recent years, numerous studies 
have assessed the role of T-cell immunological monitoring to determine the risk of CMV disease 
after solid organ and allo-HSCT.
31–37
 In both settings, after documenting CMV-specific T-cell 
responses, observation in the wait of a spontaneous viral clearance, with no or only short term 
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administration of any antiviral treatment, could be considered. However, if poor or absent CMV-
specific T-cell responses are observed, more intensive viral monitoring and more aggressive 
antiviral prophylaxis or therapy strategies may be considered. The impact of CMV-specific immune 
reconstitution was variably associated with lower incidence of CMV infection/disease, lower rate of 





Role of recent agents  
 Letermovir (LMV) – LMVbelongs to a new class of anti-CMV drugs. It inhibits the viral 
terminase complex by targeting the subunit UL56. Its antiviral activity is highly specific for CMV 
and lacks inhibitory activity against other viruses such as HSV, EBV, HZV, HHV6 and adenovirus. 
Interestingly, no cross-resistance has been reported between LMVand other agents including 
ganciclovir, foscarnet or cidofovir. In addition, based on the data currently available, primary 
resistance to LMVappears a rare event
17
. 
Pharmacokinetics LMV is available as oral or intravenous formulation. It is a weak to moderate 
inhibitor of CYP3A resulting in increased levels of sirolimus, tacrolimus and amiodarone; a weak to 
moderate inducer of CYP2C9/19 resulting in decreased levels of voriconazole and PPI, and an 
inhibitor of OATP1B1/3 (organic anion transporting polypeptide). LMV has a remarkable 
interaction with cyclosporine (CSA), whose plasmatic levels may be increased during treatment.  
CSA is catalyzed by CYP3A4 and the effects of LMVon CSA may be explained by the inhibition of 
intestinal and hepatic CYP3A4 and/or P-gp. In addition, CSA may inhibit liver transporters such as 
ATP-binding cassette transporters resulting in increased levels of letermovir: according to this 
observation, the dose of LMVmust be halved when CSA is co-administered. Table 1 summarizes 
the  relevant  interactions between LMVand the agents most frequently used in hematology. 
Clinical Trials 
A pivotal phase II study was conducted in CMV seropositive recipients of allo-HSCT from matched 
related and unrelated donors.
38
 Patients were randomized to receive either CMV prophylaxis with 
LMVat three different doses (60 mg-120 mg-240 mg QD) or placebo for 12 weeks after 
engraftment. All-cause prophylaxis failure was defined as detectable CMV DNAemia and/or CMV 
disease or drug discontinuation prior to day 84 due to any reason. CMV prophylaxis failure rate was 
significantly higher in patients who received placebo (64%) as compared to those who received 
LMVat the dose of 120 mg (32%) and 240 mg (29%)  (p 0.01 and 0.007 respectively). Of note, in a 
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post-hoc analysis, no cases of “virological failure” were observed in patients who received LMVat 
240 mg after excluding patients with detectable CMV DNAemia at baseline, as compared to 24% of 
the patients in the placebo group. No hematological toxicity or nephrotoxicity were reported with 
the administration of LMV. 
Based on the encouraging results of this study, a phase III double-blind, placebo-controlled trial was 
designed to assess the efficacy of prophylaxis with LMVat the dose of 480 mg QD (240 mg QD 
with concomitant cyclosporine administration) in adult CMV seropositive patients undergoing allo-
HSCT
18
. Patients received LMVor placebo within a median of  9 days after the graft and for up to 
14 weeks after transplantation. The primary end point was the proportion of patients with clinically 
significant CMV infection, defined as CMV DNAemia leading to preemptive therapy or CMV 
disease. Overall, fewer patients in the LMV group than in the placebo group had clinically 
significant CMV infection by week 24 (37% vs 61%, p<0.001). CMV disease was observed in 1.5% 
of patients in the LMVgroup and 1.8% in those of the placebo group. The gastrointestinal tract was 
involved in all cases. Of note, the beneficial effect of LMVwas more evident in the high-risk group 
defined as patients grafted from mismatched related, unrelated or haplo-identical donors, patients 
who received cord blood  or T-cell depleted transplants and patients with grade IIgraft-vs.-host 
disease (GVHD). The frequency of severe adverse effects was similar in the two groups. 
 Brincidofovir (BDF) – recently published results from the randomized double-blind, 
placebo-controlled Phase III clinical trial (SUPPRESS) of oral BDF for CMV-seropositive allo-
HCT patients were disappointing
39
. At the dosage of 100 mg twice weekly, the drug did not 
decrease CMV disease/reactivation requiring pre-emptive therapy through week 24 as compared to 
placebo group. BDF-associated diarrhoea – already observed in the phase 2 trial CMX001-201 – 
could not always be differentiated from gastrointestinal (GI) manifestations of GVHD. This resulted 
in more frequent immunosuppressive treatments for presumed GI manifestations of grade III acute 
GVHD that may partly have contributed to higher rates of non-relapse mortality. As the Authors 
stated, a new intra-vascular formulation of BDF is warranted for a new accurate examination of its 
efficacy and tolerability among transplant recipients. 
 Maribavir (MRB)–MRB inhibits viral UL97 kinase. It was employed at the dose of 100 mg 
in a multicenter, randomized, double blind, phase III study on CMV prophylaxis in  allo-HSCT 
recipients which failed to meet the study endpoints. 
40
It was recently proved to be effective at much 
higher doses of 400 mg /800 mg /1200 mg twice daily for resistant/refractory CMV infection in a 
recent randomized trial. 
41
In the light of these results, MRB obtained the breakthrough status 
designation by the Food and Drug Administration. Drop-out rate secondary to adverse events 
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washowever quite high at 34%. Of note, 13 patients developed mutations conferring MRB 
resistance. Two prospective trials are currently ongoing. The first (NCT02931539) will evaluate 
MRB 400 mg twice daily for eight weeks in patients with resistant/refractory CMV infections. 
CMV viremia clearance is the primary study endpoint. The second (NCT02927067)will compare 
efficacy and safety of MRB at 400 mg to valganciclovir at 900 mg in terms of CMV viremia 
clearance in asymptomatic transplant recipients. 
 
CMV vaccination 
 Though there is no currently licensed anti-CMV vaccine available, a number of vaccination 
strategies are under investigation. The induction of both T-cell and humoral immunity is a 
fundamental step toward the ideal anti-CMV vaccine. Here we include the strategies considered 
most advanced in the setting of allo-HSCT. 
 DNA-plasmid vaccines – In 2012 Kharfan-Dabaja et al. described the results from a phase 
II, placebo-controlled trial of a CMV DNA vaccine (TransVax) in allo-HSCT recipients. TransVax 
vaccine plasmids encode two CMV antigens, glycoprotein B and the phosphoprotein 65(pp65), 
designed to elicitboth host humoral and cellular immunity respectively. Although there was no 
apparent advantage in the vaccine arm as compared to the placebo group in terms of requirements 
for anti-CMV therapy (p= 0.14), there was a significant trend for a reduction in CMV viremia 
episodes and improvement in time-to viremia events in the vaccine arm.
12
 However, disappointing 
results were reported in the randomized, double-blind, placebo-controlled phase III study HELIOS 
(NCT01877655) with the TransVax vaccine ASP0113 – a bivalent DNA vaccine encoding 
glycoprotein B antigens and pp65 -  in 514 CMV-seropositive allo-HSCT recipients. Overall, the 
study failed to meet both primary – a composite endpoint of overall mortality and CMV end-organ 
disease within the first year post-transplant - and secondary – time to first CMV viremia and first-
use of antiviral therapy - end points. 
 Peptide vaccines - encouraging results came from CMVPepVax, an investigational peptide 
vaccine combined with an adjuvant, designed to control CMV infection in seropositive allo-HSCT 
recipients through the expansion of effector T cell subsets targeting pp65 CMV surface protein.
42
 
Among patients without viremia, CMVPepVax was able to reconstitute consistent levels of pp65-
specific T cells, with enhanced the engagement of different effector T cell phenotypes.
43
 Most 
importantly, this peptide vaccine provided the proof of concept that allo-HSCT recipients are able 
to mount a vaccine-driven CMV-specific T-cell response within an early post-transplant timeframe. 
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However, since the product is HLA A*0201-restricted, its availability is limited. Overall, to 
augment the potential anti-CMV effect of adoptively transferred donor-derive T cells, Gottlieb et al. 
tested the additional benefit of adjuvant CMV peptide-pulsed dendritic cell vaccination to 
prophylactic donor-derived CMV-peptide specific T cell infusion in four allo-HSCT recipients. All 
patients developed CMV specific immune reconstitution. The safety profile was acceptable with 
only one patient developing grade III acute GVHD.
15
 
 Vectored vaccine–Encouraging clinical findings were reported using the wild-type non-
recombinant modified vaccine Ankara (MVA) in a randomized, placebo-controlled double-blind 
study in 24 allo-HSCT recipients
16 
and then the MVA-based Triplex vaccine (encoding three CMV 
antigens: pp65, IE1 and IE2) in a phase I trial on healthy individuals.
17
 Confirmative results from 
the National Cancer Institute-sponsored phase II randomized, blinded and placebo-controlled 
multicentre trial, to evaluate the protective function of Triplex vaccine in CMV-seropositive allo-
HSCT recipients (NCT02506933) are eagerly awaited. The Triplex vaccine is also being tested in 
peripheral blood stem cell donors in a phase II trial (NCT03560752), designed to evaluate the 
prevention of CMV viremia in their recipients. 
 
Cytomegalovirus-specific adoptive T cell therapy 
 Virus-specific T cells are able to protect the host from developing overt viral disease. Direct 
infusion of CMV-specific T cells is the logical application of antiviral immunity restoration in 
patients lacking immune-competence.
45
 In the setting of allo-HSCT, the cellular product can be 
obtained both from the transplant donors or generated from third-party donors. The adoptive 
transfer of virus-specific T cells from the transplant donor has proven to be safe and effective in 
several clinical experiences. However, some limitations exist. First, the product can be obtained 
only if donor cells are available; second, the donor has to test seropositive for the targeted virus; 
third, the generation procedure is time consuming and costly; last, the final product is only patient 
specific.  
 An alternative process is to generate partially HLA- matched off-the shelf cryopreserved 
products from third-party donors, although strong evidence of long-term safety and in vivo 
persistence have only partially been demonstrated. Different selection strategies have been 
employed to obtain CMV-specific T cells products (i.e. in vitro stimulation and expansion, 
employment of peptide-HLA multimers, cytokine-capture techniques). A report from Lee et al. on 
results of a multicentre study of banked third-party virus-specific (CMV, EBV and adenovirus) T 
cells for 50 patients with refractory viral infections after allo-HSCT, showed an encouraging short-
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term antiviral response of 74% at 6-weeks, with only four later progressions in responders.
23 
Withers et al. treated allo-HSCT recipients with persistent/refractory CMV infections (n= 28), with 
third-party, ex-vivo expanded, partially HLA-matched (median HLA-matched antigens of the 
product was 2 out of 6 HLA-antigens) virus-specific T cells, at a median of 75 days post-transplant, 
in a multicentre phase I trial. Twelve-month overall response was 93% with a cumulative incidence 
of complete remission of 76%. Of note, all three patients with active tissue infection were 
successfully treated after only one infusion. Overall, two patients developed de novo acute GVHD 
and one of them died from steroid-refractory grade Iv intestinal GVHD. Chronic GVHD was 
observed in 5 patients, in only one severe. The Authors demonstrated that viral replication control 







 In a phase I/II trial, investigators from Germany treated sixteen allo-HSCT recipients with 
refractory CMV infections with a single infusion of ex vivo streptamer-isolated CMV-specific T 
cells, generated either from their transplant donors (n= 8) or from partially HLA matched third-
party donors (n= 8). Better overall response rates were seen in those who received infusions from 
their own donors with a complete response rate of 64%.
25 
Pei et al. reported on 32 haplo-identical 
HSCT recipients with CMV refractory infections, including ten patients with active disease, treated 
with CMV-specific cytokine-induced T cells from CMV-seropositive healthy donors. A total of 
84% of the patients cleared the infection within one month from the T cell infusion. No recurrence 
was reported. Interestingly, the Authors found that the exhausted phenotype of CMV specific T 
cells of patients suffering from repetitive CMV infections/disease could be abrogated by the 
adoptive transfer of CMV-specific T cells in responding patients.
26
Blyth et al. treated 30 allogeneic 
HCT patients with persistent/recurrent viral infections. Mostly due to CMV ( n= 28) with partially 
HLA-matched third-party ex vivo expanded virus-specific T cells. Complete viral clearance was 
achieved in 76% without product-related infusion toxicity or de novo GVHD onset. Viral control 
persisted more than 100 days in all responders. Antiviral therapy was re-introduced in 5 patients. 
Increase of CD8+ effector T-cells was associated with immune-control of viral infections. In 
responders, the control of viral replication was not associated with persisting CMV-specific T cells 
from third-party donors, whose DNA was not detectable beyond day 27 from the infusion. The 
Authors speculated an indirect putative role of third-party virus-specific T cells which may enhance 
recovery of HSCT donor-derived virus-specificimmunty.
27 
 Many clinical trials are actively recruiting patients to test the efficacy of adoptive virus-
specific (both CMV and multi-virus) T-cell therapy in the setting of allo-HSCT or solid organ 
transplants (NCT02982902 - NCT01646645 - NCT02210078 - NCT02532452 - NCT02136797 - 
12 
 
NCT03067155 - NCT02702427). At the moment, there are no published results from randomized 
clinical trials evaluating CMV-directed T cell adoptive therapy.Interestingly, recent reports showed 
that strain-specific antibodies exerted anti-CMV reactivation activity and that the active transfer of 
these antibodies intoHSCT recipients is effective in preventing virus reactivation/disease in murine 
preclinical models.
47
 This fascinating observation that humoral immunity holds a relevant role in 
the complex process of CMV reactivation after transplant may be a potential fertile seed for new 
unexpected therapeutic applications.  
 
5. Expert commentary 
 Despite recent advances, management of CMV in allo-HSCT recipients remains an unmet 
need. With novel therapeutic and diagnostic strategies, the clinical approach to CMV 
reactivation/infection and disease is rapidly evolving. The role of novel agents, such as LTM in 
particular, may highly contribute to design a new therapeutically paradigm that shifts from 
preemptive approaches to more effective prophylaxis schedules. Toxicity profiles and efficacy of 
new anti-CMV agents should be compared with that of current “standard-of-care” antiviral drugs. 
Donor-derived or third-party derived CMV specific T cells transferred after allo-HSCT could 
contribute to reduce the impact of CMV infection/disease on clinical outcomes. Moreover, the 
emerging pivotal roles of both cell-mediated immunologic monitoring and virological load testing 
are clinically evident. In summary, the integration of novel antiviral therapies including CMV 
specific T cell therapies, standardized molecular techniques for virological testing and immunologic 
assays, may be currently combined into one whole strategy to fight a life-threatening post-transplant 
complication.  
6. Five-year view 
 Future guidelines of CMV reactivation/infection treatments may include strategies to define 
high risk patients during the pre-transplant work up (i.e. baseline CMV serology, type of transplant, 
donor-recipient HLA compatibility) and tailored-made interventions based on a watchful 
prospective monitoring of viral replications from blood (and marrow) samples. A more pronounced 
integration of the kinetics of viral load coupled with specific molecular targets of novel antiviral 
therapy will guide clinicians at the bedside to individualize treatments that could limit toxicity while 
sparing antiviral effects. Moreover, the contribution of CMV specific adoptive T-cell therapies may 





• Most current antiviral drugs against CMV remains associated with severe side effects and 
potential drug-resistance despite remarkable process.  
• However newer antiviral compounds are emerging as promising agents against CMV-
resistant strains and may have a role in both the prophylactic/pre-emptive and therapeutic 
settings.  
• Prospective CMV monitoring in the virology lab will be a key factor to guide therapeutic 
interventions and significantly improve clinical outcomes 
• Off-the-shelf third-party CMV specific T-cells alone or in combination with CMV specific 
drugs with an acceptable toxicity profile may become crucial for the treatment of life-
threatening CMV disease in critically ill patients.   
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